Related Experiment Video
Updated: May 29, 2026
10:09
Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease
Published on: February 14, 2012
Opioidergic interactions between striatal projection neurons.
Craig P Blomeley1, Enrico Bracci
1Faculty of Life Sciences, University of Manchester, Manchester M139PT, United Kingdom.
Summary
Medium spiny neurons (MSNs) in the striatum communicate via opioid neuropeptides. This study reveals a novel, micro-opioid-dependent inhibition between MSNs, impacting striatal dynamics.
Area of Science:
- Neuroscience
- Cellular Signaling
- Neuropharmacology
Background:
- Medium spiny neurons (MSNs) are the primary output neurons of the striatum.
- MSNs release opioid neuropeptides, but their function in synaptic transmission is poorly understood.
- Previous studies focused on exogenous opioid receptor activation, not endogenous opioid signaling.
Purpose of the Study:
- To investigate the role of synaptically released opioids in modulating corticostriatal neurotransmission.
- To explore inter-neuronal communication between MSNs mediated by endogenous opioids.
- To elucidate the cellular mechanisms underlying opioid-mediated effects in the striatum.
Main Methods:
- Performed single and paired whole-cell recordings in rat striatal slices.
- Electrically stimulated corticostriatal fibers and activated MSN axons antidromically.
- Utilized micro-opioid receptor antagonist (CTOP) and delta-opioid receptor antagonist (SDM25N) to assess opioid involvement.
Main Results:
- Antidromic activation of MSN axons induced robust, time-dependent inhibition of evoked corticostriatal responses.
- This inhibition was specifically blocked by the micro-opioid antagonist CTOP, not the delta-opioid antagonist.
- Paired recordings showed that MSN bursts inhibited synaptic responses in neighboring MSNs, indicating direct inter-neuronal opioid communication.
Conclusions:
- Synaptically released opioids mediate a novel form of communication between MSNs in the striatum.
- This opioid signaling pathway, dependent on micro-opioid receptors, influences corticostriatal transmission.
- The findings suggest a new cellular mechanism for competitive interactions and network dynamics within the striatum.
Related Concept Videos
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...